.jpeg)
The remarkable efficacy of Asciminib
Asciminib (Asciminib) exerts its therapeutic activity by inhibiting the oncogenic protein responsible for chronic myeloid leukemia (CML) proliferation. It can be taken by mouth once or twice daily, depending on the condition being treated. It can be used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML) with the T315I mutation, a typically refractory disease, by increasing the total daily dose 5-fold compared with standard therapy (80 mg daily vs. 400 mg daily). As with many other chemotherapeutic agents, treatment with aceminib can cause various forms of myelosuppression, including thrombocytopenia and neutropenia.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
